MEDICINA Y CIRUGIA
Saila
![Foto de Luis Fernando](/img/nophoto.png)
Luis Fernando
López Cortés
Luis Fernando López Cortés-rekin lankidetzan egindako argitalpenak (29)
2024
2019
-
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
Medicine (United States), Vol. 98, Núm. 32
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2016
2015
-
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
-
Low efficacy of pegylated interferon plus ribavirin plus nitazoxanide for HCV genotype 4 and HIV coinfection
PLoS ONE, Vol. 10, Núm. 12
-
Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term
Hepatology, Vol. 61, Núm. 5, pp. 1503-1511
2014
-
A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate
Clinical Infectious Diseases, Vol. 58, Núm. 1, pp. 130-133
-
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV
The Lancet Infectious Diseases
-
Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population
PLoS ONE, Vol. 9, Núm. 5
-
Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients
PLoS ONE, Vol. 9, Núm. 7
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
-
Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients
AIDS, Vol. 27, Núm. 16, pp. 2541-2549
-
Risk of liver decompensation among HIV/Hepatitis C virus-coinfected individuals with advanced fibrosis: Implications for the timing of therapy
Clinical Infectious Diseases, Vol. 57, Núm. 10, pp. 1401-1408
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
2012
-
Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients
Hepatology, Vol. 56, Núm. 4, pp. 1261-1270
-
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
AIDS, Vol. 26, Núm. 13, pp. 1721-1724
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726
2010
-
Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/ hepatitis C Virus-Coinfected patients
Journal of AIDS and Clinical Research, Vol. 1, Núm. 3